Dr. Naoki Chiba, MD, MSc, FRCPC, AGAF, CAGF, FACG

University of Rochester Medical Center 
Professor of Clinical Medicine
Division of Gastroenterology and Hepatology 
Strong Memorial Hospital
Highland Hospital
Rochester, NY

Dr. Chiba is a general gastroenterologist and hepatologist with the University of Rochester, NY. Previously, he practiced community GI and ERCP in Guelph, ON and Charlottetown, PEI. After a long affiliation with McMaster University, he is now Professor of Clinical Medicine at the University of Rochester Medical Center. He received his MD (Cum Laude) in1986 from UWO. He completed gastroenterology and research training fellowships at McMaster University in 1992 and in 2004, he completed his Masters in Health Research Methodology at McMaster. He has authored 95 peer-reviewed publications and book chapters and participated as principal investigator in over 70 multi-centre clinical trials. Primary clinical interests focus on acid related disorders and evidence based medicine. Interests include golf and his beloved bearded collies, Indy and Goro.  

Presentation Overview:

Eosinophilic esophagitis is now a dominant topic. Elimination diets, even just lactose may benefit many. PPIs remain first line drug therapy and while patients do well, there is still persistent histological eosinophilia (Sa1279). Do we treat the patient of histology? For steroids, budesonide is better than fluticasone (Sa1301). Dupilumab (monoclonal antibody blocking interleukin 4 and interleukin 13) is an option for those that fail conventional therapy (Sa1269). New drugs target different mechanisms. Mepolizumab (anti-interleukin 5) reduces eosinophil counts but dysphagia non-significantly (Oral 463). Benralizumab (anti-interleukin 5Ra) also reduce eosinophils but not symptoms (Oral 610). Sleeping on the left-lateral reduces nocturnal reflux (Su1316). Vonoprazan in more effective than lansoprazole (Su1312). Tegoprazan does not delay gastric emptying (EP124). Fexuprazan is not affected by timing of dosing (Su1311). Lastly, bismuth added to high dose PPI + amoxicillin improves efficacy for H. pylori eradication (Oral 613).  

Session Learning Objectives:

• Participants will learn about the most important information from the four best new research abstracts presented at DDW 2023 in upper GI disorders. 
• Participants will learn about new treatments that will impact their practice. 
• Participants will learn new concepts in areas relevant to their practice.